FIELD: biotechnology.
SUBSTANCE: described is a method of creating a target panel for investigating target genomic regions to identify predictive genetic biomarkers of potential effectiveness and/or resistance to immune checkpoint (CI) inhibitors. Method involves genetic analysis of resection or biopsy material of tumor tissue of patient with diagnosed malignant neoplasm (MNP) before the beginning of the course or during immunotherapy based on immune checkpoint inhibitors—anti-PD-l or anti-PD-L1 preparations, namely: laboratory extraction of DNA from a sample of tumor material, measurement of concentration of extracted DNA, preparation of DNA libraries using tumor DNA as a matrix for amplification of target genomic regions during PCR with specific primers, sequencing of DNA libraries, subsequent bioinformatic processing of sequencing results, interpretation of biological and clinical significance of genetic variants detected by results of targeted sequencing, identification of predictive genetic biomarkers of potential efficacy and/or resistance to immunotherapy with immune checkpoint inhibitors based on target genome regions including coding sequences of 34 genes: JAK3, JAK2, MDM2, CD274, PBRM1, B2M, ERBB2, IFNGR1, CD8A, JAK1, MET, BAP1, POLE, POLD1, EGFR, LAG3, BRAF, HAVCR2, MLH1, KRAS, IFNG, ALK, PIK3CA, IDO1, AXL, TP53, STATI, SMAD4, ROS1, ARID1A, PTEN, PDCD1LG2, STK11, VHL), as well as sections of 9p24.1 locus: genes JAK2, PD-L1, and PD-L2 and intergenic regions.
EFFECT: invention can be used for selection of anticancer therapy or determination of its possible effectiveness.
12 cl, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DIFFERENTIAL DIAGNOSTICS OF TYPE OF STOMACH CANCER BY IMMUNOHISTOCHEMICAL TESTING METHOD | 2023 |
|
RU2813670C1 |
METHOD FOR MINIMALLY INVASIVE DIAGNOSIS OF LUNG CANCER BY FRAGMENTED CIRCULATING FREE DNA BASED ON MACHINE LEARNING METHODS | 2023 |
|
RU2820322C1 |
METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN MELANOMA | 2021 |
|
RU2766739C1 |
METHOD OF OBTAINING A CULTURE OF LYMPHOCYTES ENRICHED IN TUMOR-SPECIFIC T-LYMPHOCYTE CLONES AND CELL CULTURES OBTAINED USING THE SPECIFIED METHOD | 2022 |
|
RU2808595C1 |
VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2008 |
|
RU2482491C2 |
METHODS OF DETECTING AND MONITORING CANCER BY PERSONALIZED DETECTION OF CIRCULATING TUMOR DNA | 2019 |
|
RU2811503C2 |
VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2013 |
|
RU2635525C2 |
BIOMARKER PANEL AND METHODS FOR DETECTING MICROSATELLITE INSTABILITY IN VARIOUS TYPES OF CANCER | 2019 |
|
RU2795410C2 |
GENETIC VECTOR Ad6/3-hTERT-GMCSF CONTAINING GENOMIC SEQUENCES OF RECOMBINANT ADENOVIRUS SEROTYPE 6, HUMAN TELOMERASE PROMOTER, HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE, AS WELL AS FIBER PROTEIN GENE WITH INSERTION OF FIBER KNOB DOMAIN OF ADENOVIRUS SEROTYPE 3 WITH INCREASED TRANSDUCTION INTO TUMOR CELLS | 2023 |
|
RU2814581C1 |
METHOD FOR DETERMINING MARKERS OF PRESENCE OF TUMOR T-LYMPHOBLASTS | 2016 |
|
RU2674994C2 |
Authors
Dates
2024-05-02—Published
2023-07-10—Filed